-
Novartis India Q4 net profit rises 11% to Rs 278 crore
Drug major Novartis India on Thursday reported an 11 per cent rise in its net profit to Rs 278 crore for the fourth quarter ended December 2022.
-
Novartis India launches new drug for treatment of heart failure
Novartis India on Wednesday launched a new drug for the treatment of heart failure, the company said in a statement.
-
Novartis India appoints Vikas Bapat as new CFO
Novartis India has appointed Vikas Bapat as its new Chief Financial Officer (CFO), effective March 1, 2023.
-
Novartis India reports a strong Q3 performance, driven by growth in key businesses
Novartis India Limited (NIL) today announced its financial results for the quarter ended September 30, 2023. The company reported a strong performance, with revenue growing by 10% year-on-year to Rs. 1,238 crores. This growth was driven by strong demand for the company's key products in the pharmaceuticals, oncology, and vaccines businesses.
-
Novartis India launches new initiative to improve access to healthcare for underserved communities
Novartis India Limited (NIL) today announced the launch of a new initiative to improve access to healthcare for underserved communities in India. The initiative, called the 'Novartis Access Program', will provide free medicines and healthcare services to patients in need.
-
Novartis India receives approval for new drug to treat heart failure
Novartis India Limited (NIL) today announced that it has received approval from the Drug Controller General of India (DCGI) for a new drug to treat heart failure. The drug, called Entresto, is a combination of two existing drugs, sacubitril and valsartan.
